Pharmaceuticals 2010, 3(3), 764-781; doi:10.3390/ph3030764
Review

Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs

Karolinska Institutet, Department of Clinical Science and Education, Division of Internal Medicine, Unit for Diabetes Research, Södersjukhuset, SE-118 83 Stockholm, Sweden
Received: 15 January 2010; in revised form: 3 March 2010 / Accepted: 19 March 2010 / Published: 22 March 2010
(This article belongs to the Special Issue Antidiabetic Drugs)
PDF Full-text Download PDF Full-Text [1095 KB, Updated Version, uploaded 23 March 2010 09:04 CET]
The original version is still available [1095 KB, uploaded 22 March 2010 10:39 CET]
Abstract: Although advances have been achieved in the management of type 2 diabetes, current treatment options for patients with this disease still fail to address disease progression, glycaemic control remains suboptimal and therapies are often associated with weight gain and hypoglycaemia. Thus, new antidiabetes therapies are being sought. Glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) are incretin hormones that have been the recent focus of research. The physiological action of GLP-1, in particular, has demonstrated its potential in addressing the therapeutic needs of patients with type 2 diabetes. To exploit this action, liraglutide, a human GLP-1 analogue that shares 97% of its amino acid sequence identity with native GLP-1, has been developed. In a recent phase 3 trial programme (LEAD, Liraglutide Effect and Action in Diabetes), treatment with liraglutide was associated with substantial improvements in glycaemic control and low risk of hypoglycaemia. In addition, reductions in weight and systolic blood pressure were reported. There is also an indication that liraglutide is capable of improving β-cell function and increasing β-cell mass. Thus, liraglutide may overcome the limitations with current therapies and help to address the unmet clinical needs of patients with type 2 diabetes.
Keywords: GLP-1; liraglutide; LEAD; glycaemic control; type 2 diabetes

Article Statistics

Load and display the download statistics.

Citations to this Article

Cite This Article

MDPI and ACS Style

Sjöholm, Å. Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs. Pharmaceuticals 2010, 3, 764-781.

AMA Style

Sjöholm Å. Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs. Pharmaceuticals. 2010; 3(3):764-781.

Chicago/Turabian Style

Sjöholm, Åke. 2010. "Liraglutide Therapy for Type 2 Diabetes: Overcoming Unmet Needs." Pharmaceuticals 3, no. 3: 764-781.

Pharmaceuticals EISSN 1424-8247 Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert